Is there an association between transverse myelitis and bipolar disorder, and what are the clinical implications for screening and management?

Association Between Transverse Myelitis and Bipolar Disorder

There is no established direct correlation between transverse myelitis (TM) and bipolar disorder (BD), but both conditions can co-occur in the context of central nervous system demyelinating diseases, particularly multiple sclerosis (MS), which shares pathophysiological features with TM.

Understanding the Relationship

The evidence does not support a direct causal link between isolated transverse myelitis and bipolar disorder. However, the connection becomes clearer when examining the broader spectrum of CNS demyelinating diseases:

Key Evidence on Demyelinating Diseases and Bipolar Disorder

The most robust recent evidence shows that patients with MS have a significantly elevated risk of developing bipolar disorder 1. The 2026 meta-analysis found:

• Overall BD prevalence in MS patients: 3.2% (95% CI: 1.8-4.6%)
• Hazard ratio for developing BD: 2.5 (95% CI: 1.2-5.3)
• Odds ratio: 1.5 (95% CI: 1.1-2.0)

A concurrent 2026 study examining 4,460 MS patients and 299 NMOSD patients found BD prevalence of 3.07% overall, with NMOSD patients showing comparable risk to MS patients (OR: 1.15; 95% CI: 0.60-2.17) 2. Higher disability levels (EDSS), cerebellar symptoms at onset, single relationship status, addiction, and smoking were associated with increased BD likelihood 2.

Clinical Implications for Transverse Myelitis

While TM itself has limited psychiatric research, one study found 30% of TM patients had psychiatric disorders, with major depression (17%) being most common 3. Importantly:

• 70% of TM patients scored above threshold on psychiatric screening (GHQ-12)
• 23% showed cognitive impairment
• Psychiatric morbidity correlated with greater disability levels

The critical clinical consideration is that approximately 3.33% of acute-onset LETM cases can convert to multiple sclerosis 4, which then carries the elevated BD risk described above.

Screening and Management Algorithm

Initial Assessment of TM Patients

When evaluating a patient with transverse myelitis:

1. Determine TM characteristics that predict MS conversion:

   • Acute onset presentation
   • Longitudinally extensive involvement (LETM) - present in 76.7% of TM cases 4
   • Long spinal segment involvement on MRI (65.5% of cases) 4
   • Presence of quadriparesis, bowel/sexual dysfunction

2. Screen for demyelinating disease markers:

   • Test for AQP4-IgG and MOG-IgG antibodies 5
   • Evaluate MRI for patterns suggesting MS vs. isolated TM
   • Monitor for recurrent episodes suggesting conversion to MS

Psychiatric Screening Protocol

All patients with TM should undergo baseline psychiatric screening given the 30% prevalence of psychiatric disorders 3:

• Use structured screening tools (GHQ-12 as initial screen)
• Specifically assess for both depressive and manic/hypomanic symptoms
• Do not assume depression is the only mood disorder risk - the ratio of MDD to bipolar spectrum disorders is lower in demyelinating diseases, indicating relatively higher BD association 6

For Patients Who Convert to MS or Have Concurrent Demyelinating Disease

Implement routine psychiatric monitoring with particular attention to:

• Bipolar spectrum disorders, especially BD Type II, which may be under-diagnosed in this population 6
• Higher-risk subgroups: those with higher disability (EDSS), cerebellar involvement, and psychosocial stressors 2
• Neuroimaging findings: frontal and temporal lobe involvement, periventricular white matter lesions may represent biological substrates for BD in demyelinating disease 7

Critical Treatment Caveat

Exercise extreme caution when prescribing antidepressants to patients with TM or demyelinating diseases who present with depressive episodes 6. Always exclude bipolar disorder before initiating antidepressant monotherapy, as this can precipitate manic episodes. The elevated BD risk in this population (2.5-fold increased hazard) makes this screening essential.

Monitoring Strategy

• Baseline psychiatric evaluation at TM diagnosis
• Repeat screening at 3-month intervals during first year
• Annual psychiatric assessment thereafter
• Immediate evaluation if new neurological symptoms suggest MS conversion
• If MS develops, intensify psychiatric monitoring given the 3.2% BD prevalence and 2.5-fold increased risk 1

Common Pitfalls to Avoid

1. Assuming all mood symptoms are reactive depression - the biological substrate of demyelinating disease creates genuine increased BD risk
2. Missing BD Type II - hypomanic episodes are easily overlooked but represent significant risk in this population 6
3. Prescribing antidepressants without BD screening - can trigger manic episodes in undiagnosed BD patients 6
4. Failing to monitor for MS conversion - changes prognosis and psychiatric risk profile 4
5. Attributing psychiatric symptoms solely to corticosteroid treatment - while steroids can induce mood episodes, underlying BD risk is independently elevated 7